BIOCRYST PHARMACEUTICALS INC - COM (BCRX)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Equity / COM
Shares, excl. options Q3 2024
172M
Holdings value Q3 2024
$1.31B
Value change Q3 2024
-$17.2M
Grand Portfolio weight change Q3 2024
0%
Number of holders
253
Number of buys Q3 2024
126
Number of sells Q3 2024
-106
Average buys Q3 2024 %
+0.001%
Average sells Q3 2024 %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 172M $1.31B -$17.2M $7.60 256
2024 Q2 174M $1.08B -$20M $6.18 238
2024 Q1 179M $908M +$7.4M $5.08 235
2023 Q4 177M $1.06B -$8.59M $5.99 234
2023 Q3 175M $1.24B +$14.8M $7.08 229
2023 Q2 174M $1.23B +$15.8M $7.04 233
2023 Q1 171M $1.42B +$99M $8.34 237
2022 Q4 157M $1.8B +$87.5M $11.48 225
2022 Q3 149M $1.87B -$40.2M $12.60 217
2022 Q2 152M $1.61B +$202M $10.58 207
2022 Q1 128M $2.07B +$162M $16.26 221
2021 Q4 118M $1.62B +$189M $13.85 199
2021 Q3 103M $1.48B -$23.6M $14.37 194
2021 Q2 105M $1.65B +$25.6M $15.81 190
2021 Q1 105M $1.06B -$142M $10.17 187
2020 Q4 121M $898M -$43.7M $7.45 173
2020 Q3 128M $438M -$23.5M $3.44 151
2020 Q2 133M $635M +$96.6M $4.76 161
2020 Q1 123M $245M -$37.9M $2.00 127
2019 Q4 137M $473M +$126M $3.45 132
2019 Q3 98.7M $283M -$6.97M $2.87 111
2019 Q2 100M $380M -$87.9M $3.79 112
2019 Q1 101M $826M +$1.49M $8.14 131
2018 Q4 101M $817M +$8.89M $8.07 119
2018 Q3 100M $764M +$73.7M $7.63 111
2018 Q2 87.5M $501M -$8.61M $5.73 99
2018 Q1 89M $425M -$6.56M $4.77 98
2017 Q4 90.3M $443M +$30.2M $4.91 112
2017 Q3 83.6M $436M +$74.6M $5.24 115
2017 Q2 68.7M $382M +$5.09M $5.56 109
2017 Q1 67.6M $566M +$138M $8.40 114
2016 Q4 58.4M $370M +$9.93M $6.33 110
2016 Q3 56.5M $249M +$22.2M $4.41 97
2016 Q2 51.5M $146M -$10.4M $2.84 92
2016 Q1 54.4M $154M -$58.2M $2.83 103
2015 Q4 63M $650M -$21.1M $10.32 117
2015 Q3 64.9M $740M +$19.4M $11.40 123
2015 Q2 63M $941M -$26.3M $14.93 121
2015 Q1 65.1M $588M +$36.3M $9.03 98
2014 Q4 60.8M $739M +$25.3M $12.16 89
2014 Q3 56.7M $554M +$30.5M $9.78 100
2014 Q2 53M $676M +$132M $12.75 99
2014 Q1 43.5M $461M +$94M $10.58 87